"it is great to find out that some reasoning and a prescription has helped someone turn their life around" Dr Alexander Lisinski, resident psychiatrist at Sahlgrenska University Hospital and researcher at the Department of Pharmacology, Sahlgrenska Academy, Gothenburg, Sweden, ...
Watch three experts discuss the role of FcRn inhibitors in the management of generalized myasthenia gravis
Experts discuss optimization of multidisciplinary care of alpha-mannosidosis along the patient’s lifespan.
Over the past two decades, the understanding and management of multiple sclerosis (MS) have advanced dramatically, reshaping long-held views of the disease. MS is now increasingly seen as a continuous spectrum rather than a condition with distinct phases, with evidence showing it can begin silently, even before clinical symptoms emerge. Technological and diagnostic innovations have enabled the detection of early brain changes and biomarkers, opening doors to earlier diagnosis and intervention. New diagnostic criteria allow MS to be identified without a clinical event, and studies on disease-modifying therapies (DMTs) support the benefits of early treatment. A major shift in treatment strategy is also underway, emphasizing early, aggressive approaches and therapies that target progression rather than just relapses, which are no longer seen as the main driver of long-term disability. A pivotal development in MS research is the confirmation of Epstein–Barr virus (EBV) as a fundamental trigger of the disease, with new evidence pointing to specific viral protein regions as higher-risk factors. Despite these strides, MS research remains a dynamic and evolving field, with much still to be uncovered beneath the surface.
The FDA has approved tenecteplase (TNKase) for the treatment of acute ischemic stroke (AIS) in adults, marking the first new stroke-specific thrombolytic approval in nearly three decades. Administered as a single five-second intravenous bolus, tenecteplase allows for faster administration compared to the current standard of care alteplase, which is administered as a bolus-plus-infusion regimen.
Brain Awareness Week, taking place from March 10-16, 2025, is a global campaign dedicated to fostering public enthusiasm and support for brain science, organised by the Dana Foundation. Each March, participants worldwide organize imaginative activities that highlight the wonders of the brain and the profound impact of neuroscience on our daily lives.
The prevalence of unruptured intracranial aneurysms (IAs) is approximately 3% of the population, with incidence on the rise due to the increased utilization of neuro-imaging for diverse objectives.1,2 The average risk of rupture for unruptured IA is estimated to vary from 0.3% ...
Seizures are one of the most frequent neurological disorders in neonates − the incidence of seizures in infants born at term is 1–3 per 1,000 live births, and is even higher in both preterm and very-low-birth-weight infants at 1–13 per 1,000 live births.1 Seizures may ...
Sanofi at ECTRIMS 2024. Join MS experts as they examine disability accumulation through the lens of personalised care, biomarkers, and clinical trial design. Hear their perspectives on the complexities of balancing improved relapse management with the ongoing challenge of disability accumulation.
Living with multiple sclerosis (MS) can present numerous challenges, and for individuals in rural communities, those challenges can be even more pronounced. In rural areas, access to MS specialists can be limited, and often rural hospitals and clinics are the primary locations where residents seek diagnosis and care for MS.
Three experts share insights into the treatment and care of patients with NF1 from childhood to adulthood.
The phase 3b SMART study has shown that 83% of paediatric patients with spinal muscular atrophy (SMA) weighing between 8.5 and 21 kg achieved significant motor improvements following treatment with intravenous onasemnogene abeparvovec in a recent article published in Neurology.
Huntington’s disease (HD) is a neurodegenerative disease inherited in an autosomal dominant manner. It is caused by an expansion of cytosine, adenine, guanine (CAG) repeats within the huntingtin (HTT) gene, which is located on chromosome 4. This pathological expansion of ...
The International Neuromodulation Society (INS) recently welcomed Prof. Konstantin Slavin as its new President. A distinguished neurosurgeon with expertise in functional and stereotactic neurosurgery, Prof. Slavin brings over 30 years of experience, including notable contributions to chronic pain management, movement disorders, epilepsy, and psychiatric conditions. touchNEUROLOGY extends its best wishes for a successful presidency.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.